Neurology® Podcast

1) Relationship between Risk Factor Control and Vascular Events in the SAMMPRIS Trial 2) What's Trending: 2017 AAN Annual Meeting3) Topic of the Month: neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 24, 2017 issue of Neurology. In the first segment, Dr. Joseph Carrera talks with Dr. Tanya Turan about her paper on risk factor control and vascular events in the SAMMPRIS trial. Dr. Ted Burns talks with Christy Phelps about the 2017 AAN Annual Meeting for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Anthony Amato on myositis. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Turan serves on a scientific advisory board for Boehringer Ingelheim; serves on blinded Neurological Events Adjudication Committees for Boehringer Ingelheim and W.L. Gore and Associates; is Review Editor for Frontiers in Endovascular and Interventional Neurology and specialty editor of Frontiers in Neurology; serves on editorial boards for World Journal of Neurology, Brain and Behavior, and Annals of Translational Medicine; and received research support from NIH/NINDS K23 award for activities in the SAMMPRIS trial.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amato serves on medical advisory boards for MedImmune, Amgen, Novartis, DART, Biogen, Acceleron, and DSMB for NIH; is Associate Editor for Neurology and Muscle & Nerve; possesses publishing royalties for Neuromuscular Disease (McGraw-Hill 2016); serves as medical consultant for MedImmune, Amgen, Biogen, Novartis, Acceleron, Analgesic Solutions, Up-to-Date, and Best Doctors; and receives research support from Novartis, Alexion, and Amgen.Christy Phelps serves as Deputy Executive Director for the AAN.Dr. Carrera reports no disclosures.

1) Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 17, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Aneesh Singhal about his paper on glucocorticoid-associated worsening of reversible cerebral vasoconstriction syndrome. Dr. Ted Burns talks with Dr. Roy Strowd about upcoming changes regarding the Neurology Resident & Fellow section for our "What's Trending" feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Volker Straub on limb-girdle dystrophy. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Aneesh Singhal has served on the scientific advisory boards of Biogen and DSMB; has served on the editorial board of Medical Gas Research; has received publishing royalties for the book Reversible Cerebral Vasoconstriction Syndromes; has been a consultant to Biogen; has acted as an event adjudicator for the Thrombolysis in Myocardial Infarction (TIMI) Trial Group; has received research support from Boehringer Ingelheim, NIH-NINDS, the American Academy of Neurology, UpToDate, and Medlink; and has served as a medicolegal expert witness for individual cases concerning stroke. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Straub has served on the scientific advisory boards for Pfizer, Italfarmaco, Audentes Therapeutics, Bristol-Myer Squibb, Summit Therapeutics, Tivorsan, and the Nationwide Children's Hospital; has received travel funding and speaker honoraria from Sanofi Genzyme; has served on the editorial boards of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and PLoS Currents Muscular Dystrophy; has been a consultant for Sanofi Genzyme; and has received research support from Sanofi Genzyme, BioMarin, Ionis Pharmaceuticals, Sarepta Therapeutics, Ultragenyx, the European Commission, the UK Medical Research Council, Newcastle University, the Parent Project Muscular Dystrophy, the Association Fracaise Contre les Myopathies, the LGMD2I Research Fund, the Wellcome Trust, the Sylvia Aitken Charitable Trust, Muscular Dystrophy UK, and Action Medical Research.All other participants have no disclosures.

1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH.Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.

1) The Effects of Orthostatic Hypotension on Cognition in Parkinson's Disease 2) What's Trending: Carotid surgery trials3) Topic of the Month: Neuromuscular topicsThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Justin Centi about his paper on the effects of orthostatic hypotension on cognition in Parkinson disease. Dr. Andy Southerland is interviewing Dr. Seemant Chaturvedi for our "What's Trending" feature of the week about urgency for carotid surgery trials. In the next part of the podcast, Dr. Ted Burns interviews Dr. Michelle Mauermann about neuromuscular topics. Disclosures can be found at www.neurology.org.DISCLOSURES: Dr. Barrett has received research support from Axovant Sciences, Inc., the Virginia Center of Alzheimer's and Related Diseases, and the Department of Defense.Dr. Centi has been an employee of Commonwealth Psychology Associates LLC and Harvard Medical School/Partners Consortium in Neuropsychology; and has received research support from NIH-NINDS.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Chaturvedi has been a consultant for Merck; has served on the executive committee of ACT I study and CREST 2 study; serves on the editorial boards of Neurology, the Journal of Stroke & Cerebrovascular Disease, Stroke, and NEJM Journal Watch Neurology; has received research support from Boehringer-Ingelheim, NINDS, and the FDA; and has received compensation for expert witness testimony.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties for book Autonomic Neurology; and receives research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.All other participants have no disclosures.

The first interview is with Dr. Jeff Ratliff and Dr. Kailash Bhatia on the topic of dystonia. The second is with Dr. Alberto Espay and Dr. Roger Elble on tremor. These interviews were first released on November 1 and November 8, 2016. In the third week's interview, originally released on November 15, 2016, Dr. Alberto Espay interviews Don Gilbert on tics. In the fourth interview, from November 22, 2016, Dr. Ratliff speaks with Dr. Ruth Walker about chorea. The fifth and final interview, originally released on November 29, 2016, is an interview with Dr. Espay and Dr. Steven Frucht on the topic of myoclonus.

1) AAN guideline summary: Treatment of restless legs syndrome in adults 2) What's Trending: Interview with Dr. Steven Messé on why acute ischemic stroke patients are not receiving IV tPA3) Topic of the month: Neurology Today story about cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out forThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. John Winkelman about the AAN guideline summary on the treatment of restless legs syndrome in adults. Dr. Andy Southerland is interviewing Dr. Steven Messé for our "What's Trending" feature of the week about his paper on why are acute ischemic stroke patients not receiving IV tPA. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Messacar and Ken Tyler about a Neurology Today story on the topic on cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out for.DISCLOSURES: Dr. Winkelman serves as Associate Editor for Sleep; serves as an editorial board member of Sleep Medicine and CNS Drugs; received honoraria from serving on the scientific advisory board of Merck Serono, Flex Pharma, UCB, Impax Pharmaceuticals, Pfizer Inc, Lacrima, Luitpold Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Xenoport, Zeo Inc., Sunovion, Insys, Takeda Pharmaceutical Company Limited, Jazz and Neurogen; receives royalties from the publication of the books: Foundations of Psychiatric Sleep Medicine and Nocturnal Leg Cramps; holds stock options in Flex Pharma; provided expert witness work for ArentFox and CantorColburn; received funding for travel from Novartis and Otsuka; currently performs neurophysiology studies as part of his practice;receives research support from Xenoport, GlaxoSmithKline, UCB, Sepracor, Pfizer Inc, Impax Pharmaceuticals, Purdue, Neurometrix and the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Messé received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for PML Consortium; is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from the NIH. All other participants report no disclosures.

1) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials2) What's Trending: Interview with Dr. Neil Garrett about his Nature Neuroscience article on dishonesty.3) Topic of the month: Neurology Today story about Zika virus and Guillain Barre syndrome detected in ColumbiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Mark Bolland about his paper on the systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Dr. Ted Burns is also interviewing Dr. Neil Garrett for our "What's Trending" feature of the week about his Nature Neuroscience paper on dishonesty. In the next part of the podcast Dr. Ted Burns interviews Dr. Carlos Pardo about a Neurology Today story on the topic of Zika virus and Guillain Barre syndrome detected in Columbia.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bolland receives research support from the Health Research Council of New Zealand.Dr. Pardo receives research support from Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH.All other participants report no disclosures.

Join Thomas Bird, an expert in human germline editing, and John Hardy, a groundbreaking researcher in Alzheimer’s genetics, as they dive into the fascinating world of neurogenetics. They discuss the latest advancements in sequencing technologies, the complexities of deciphering genetic inheritance in neurological conditions, and the ethical implications of CRISPR technology. Hardy shares insights from his research on Alzheimer's genes, while Bird emphasizes the urgent need for improved genetic counseling. Together, they navigate the future of genetic research and its transformative impact on healthcare.

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of "how to approach" myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

1) Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project2) e-Pearl topic: Transthyretin familial amyloid polyneuropathy3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Lynda Lisabeth about her paper on temporal trends in tissue plasminogen activator administration for acute ischemic stroke. Dr. Ilena George is reading our e-Pearl of the week about transthyretin familial amyloid polyneuropathy. In the next part of the podcast Dr. Jeff Ratliff interviews Dr. Ruth Walker on the topic of chorea.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publication of the book Stroke and editing the book Neurology in Practice; and receives research support from the NIH.Dr. Lisabeth receives research support from the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Walker is a consultant for Neurocrine Biosciences, Inc.; assists with Audio-Digest Board Reviews; received funding for travel from Korean Movement Disorders Society and honoraria from Neurocrine Biosciences, Inc.